Assessment of the efficacy and safety of alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis in Russian population-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Assessment of the efficacy and safety of alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis in Russian population

Published:2023 Issue:9 Volume:123 Page:76
ISSN:1997-7298
Container-title:Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova
language:en
Short-container-title:Z. nevrol. psikhiatr. im. S.S. Korsakova

Author:

Sivertseva S.A.^ORCID,Prilenskaya A.M.^ORCID,Popova E.V.^ORCID,Turova E.L.^ORCID,Volkova L.I.^ORCID,Smagina I.V.^ORCID,Elchaninova E.Yu.^ORCID,Afanas’eva A.I.^ORCID,Goncharova Z.A.^ORCID,Markova E.A.^ORCID,Yarosh N.M.^ORCID,Bakhtiiarova K.Z.^ORCID,Sherman M.A.^ORCID,Boyko A.N.^ORCID

Publisher

Media Sphere Publishing Group

Subject

Psychiatry and Mental health,Neurology (clinical)

Reference12 articles.

1. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223

2. Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis

3. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD)

4. Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis

5. Alemtuzumab induced hemodynamic change in relapsing multiple sclerosis occurs independent of corticosteroid premedication – a retrospective multicentre study

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP